Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases.

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncology. ,vol. 11, pp. 121- 128 ,(2010) , 10.1016/S1470-2045(09)70364-X

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa, Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR The New England Journal of Medicine. ,vol. 362, pp. 2380- 2388 ,(2010) , 10.1056/NEJMOA0909530

Y.-L. Wu, C. Zhou, C.-K. Liam, G. Wu, X. Liu, Z. Zhong, S. Lu, Y. Cheng, B. Han, L. Chen, C. Huang, S. Qin, Y. Zhu, H. Pan, H. Liang, E. Li, G. Jiang, S.H. How, M.C.L. Fernando, Y. Zhang, F. Xia, Y. Zuo, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study Annals of Oncology. ,vol. 26, pp. 1883- 1889 ,(2015) , 10.1093/ANNONC/MDV270

James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi-Long Wu, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 The Lancet Oncology. ,vol. 16, pp. 830- 838 ,(2015) , 10.1016/S1470-2045(15)00026-1

Maria E. Arcila, Khedoudja Nafa, Jamie E. Chaft, Natasha Rekhtman, Christopher Lau, Boris A. Reva, Maureen F. Zakowski, Mark G. Kris, Marc Ladanyi, EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Molecular Cancer Therapeutics. ,vol. 12, pp. 220- 229 ,(2013) , 10.1158/1535-7163.MCT-12-0620

Vincent A Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu-Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crino, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, James Chih-Hsin Yang, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncology. ,vol. 13, pp. 528- 538 ,(2012) , 10.1016/S1470-2045(12)70087-6

James Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, Te-Chun Hsia, Chun-Ming Tsai, Sai-Hong Ignatius Ou, Chung-Jen Yu, Gee-Chen Chang, Ching-Liang Ho, Lecia V Sequist, Arkadiusz Z Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M Lorence, Pan-Chyr Yang, Vincent A Miller, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Lancet Oncology. ,vol. 13, pp. 539- 548 ,(2012) , 10.1016/S1470-2045(12)70086-4

Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncology. ,vol. 12, pp. 735- 742 ,(2011) , 10.1016/S1470-2045(11)70184-X

Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka, Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma The New England Journal of Medicine. ,vol. 361, pp. 947- 957 ,(2009) , 10.1056/NEJMOA0810699

Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong-Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut L Geater, Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial The Lancet Oncology. ,vol. 15, pp. 213- 222 ,(2014) , 10.1016/S1470-2045(13)70604-1